Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × GIST × Clear all

Phase

Status

Completed 4 Unknown 2 Recruiting 1 Not yet recruiting 1 Approved for marketing 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 1520 Neoplasms 1291 Carcinoma, Non-Small-Cell Lung 891 Prostatic Neoplasms 823 Colorectal Neoplasms 736 Lung Neoplasms 672 Pancreatic Neoplasms 502 Carcinoma, Hepatocellular 459 Leukemia, Myeloid, Acute 448 Stomach Neoplasms 437 Ovarian Neoplasms 430 Neoplasm Metastasis 413 Multiple Myeloma 407 Recurrence 344 Melanoma 333 Uterine Cervical Neoplasms 318 Squamous Cell Carcinoma of Head and Neck 308 Head and Neck Neoplasms 306 Brain Neoplasms 292 Esophageal Neoplasms 286 Lymphoma 273 Precursor Cell Lymphoblastic Leukemia-Lymphoma 272 Endometrial Neoplasms 266 Triple Negative Breast Neoplasms 250 Rectal Neoplasms 243 Urinary Bladder Neoplasms 238 Glioblastoma 234 Sarcoma 226 Hematologic Neoplasms 223 Carcinoma, Renal Cell 218

Interventions

olverembatinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06640361 2024-12-27

A Study of Olverembatinib in SDH-deficient GIST.

Ascentage Pharma Group Inc.

Phase 3 Recruiting

GIST

Data powered by HemOnc (CC BY 4.0) Colophon ⚡